Enanta Pharmaceuticals reported $1.35M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Amgen USD 57.3B 19M Jun/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 7.69B 398.3M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 544.86M 180.93M Sep/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
J&J USD 49.04B 5.95B Jun/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 1.13B 679.48M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Novartis USD 49.01B 2.02B Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026